Transaction overview
Vance Street Capital LLC, a private equity firm based in Los Angeles, acquired Mountain Manufacturing Technologies on October 13, 2022. The deal value was undisclosed but provided strategic complementarity to Vance Street's existing portfolio company Wytech Industries within the medical device outsourced manufacturing sector. Mountain Manufacturing Technologies is a Minnesota-based manufacturer known for its advanced precision machining capabilities and R&D-driven approach in producing specialized core wires, hypotube-based components, and other intricate parts for interventional and surgical markets.
Deal structure and financing
The exact financial terms of the deal were not disclosed, including equity and debt splits. Vance Street Capital used BMO Sponsor Finance and Apogem Capital for debt financing but specific leverage metrics are unknown. The acquisition was completed with a full 100% stake by Vance Street Capital, indicating no seller retained stake or lock-up agreements. Paul Hastings served as the legal advisor to Vance Street on this transaction while Ballard Spahr LLP represented Mountain Manufacturing Technologies.
Strategic context
Vance Street's acquisition of Mountain Manufacturing aligns with its strategy of building a portfolio within medical device manufacturing and R&D-focused services. The deal allows Wytech Industries, another Vance Street portfolio company, to expand its product offerings into specialized mandrels for various sizes, shapes, and materials needed in interventional markets such as Structural Heart and Electrophysiology. Mountain's expertise in large diameter, hollow core, and grooved mandrels complements Wytech’s existing capabilities focused on high volume dead straight mandrels.
For Mountain Manufacturing Technologies, the acquisition by Vance Street Capital provides an avenue for significant growth and innovation support from a private equity firm with substantial experience in medical technology. The company founders were looking for investment partners who would share their vision for expansion and maintain employee values while advancing product development and customer service in complex medical device markets.
Regulatory path
No specific regulatory scrutiny or filings are mentioned regarding this transaction, suggesting the deal was likely reviewed by relevant U.S. authorities but did not require significant antitrust remedies due to its nature within a specialized niche of the medical device manufacturing sector. The jurisdictions involved would primarily be the United States given both parties’ locations and industry focus.